ENTITY
YiChang HEC ChangJiang Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical (1558 HK)

137
Analysis
Health Care • China
YiChang HEC ChangJiang Pharmaceutical develops, manufactures, and sells pharmaceutical products, focusing on anti-viral, endocrine and metabolic, and cardiovascular diseases. Key products include Kewei (oseltamivir phosphate), Oumeining (telmisartan), and Ertongshu (benzbromarone). The company was founded in 2001 and is headquartered in Dongguan, China.
more
bearish•Apollomics Inc
•30 Mar 2021 09:14

Pre-IPO Apollomics - Concerns on Competition and Commercialization Despite Some Promising Products

This article provided insights on its major products in the pipeline in terms of competitive landscape, strength and challenges, as well as...

Logo
942 Views
Share
bullish•Nongfu Spring
•06 Jan 2021 13:53

Full Circulation Of H-Shares: January 2021 Update

To date, 20 companies have sought approval to convert their domestic shares into H shares,  13 of which have now been given CSRC and Hong Kong...

Logo
696 Views
Share
•17 Jul 2020 12:49

Full Circulation Of H-Shares - July Update

This update is the latest in a series dating back to Legend's Conversion of Domestic Shares in June 2018, with the most recent addition CPPCC And...

Logo
721 Views
Share
bullish•ZhongAn Online
•21 May 2020 16:47

CPPCC And Full Circulation Of H-Shares

After being delayed two months, the 2020 National People's Congress and Chinese People's Political Consultative began its annual session today,...

Logo
550 Views
Share
x